Houghten Debuts Corporate Web Site; Provides Easy Access to Multiple Drug Discovery Sites

Search Blogs that Mention this News Release
Click this link to view linked Bookmarking Services
Click this link to view linked Blogging Services
Houghten Debuts Corporate Web Site; Provides Easy Access to Multiple Drug Discovery Sites
    SAN DIEGO, Feb. 21 /PRNewswire/ -- Houghten Pharmaceuticals, Inc., (HPI),
(Nasdaq: HPIP), a biotechnology company pursuing pharmaceutical drug
discovery, today announced its corporate web site located at
http://www.houghten.com.
    The HPI site provides a broad array of easily accessible information.
Through a series of links, HPI's site can connect the viewer with an
international network of companies, universities, research institutions, and
publications investigating molecular diversity as a tool for drug discovery.
The web site also provides the financial community with timely and consistent
information about HPI, and prospective employees can use the site for a
complete listing of jobs.
    "Our comprehensive web site reflects the company's commitment to several
important constituencies and its belief in using the latest technology -- both
for communication and drug discovery," stated Robert S. Whitehead, HPI's
president and chief executive officer.  "Our innovative use of links enables
researchers to reach other useful drug discovery resources."
    HPI is a drug discovery company, which utilizes combinatorial chemistry
and combinatorial biology technologies to create novel small-molecules drug
candidates.  The company leverages its technology platform by entering into
pharmaceutical alliances, enabling partners to access HPI's technologies in
exchange for licensing fees, potential milestones payments and royalties, or
by establishing joint-discovery alliances with biotechnology companies, HPI
also uses its drug discovery technologies in its internal development
programs.
    Except for the historical information contained herein, the matters
discussed in the news release are forward-looking statements that involve
risks and uncertainties, and other risks detailed from time to time in HPI's
Securities and Exchange Commission (SEC) filings.  These forward-looking
statements represent HPI's judgment as of this release.  Actual results may
differ materially from those projected.  HPI disclaims, however, any intent of
obligation to update these forward-looking statements.
SOURCE Houghten Pharmaceuticals, Inc.